Drug firm Dr Reddy's Laboratories has launched its bioequivalent version of Zometa in the USA market following USFDA’s approval.
Hyderabad based drug firm Dr Reddy’s Laboratories has recently announced its launch of generic Zoledronic Acid injections in the US market. The injection in 4 mg/5 ml strength is approved by the US Food and Drug Administration (USFDA) and is available in single use vials.
The drug, which is a bioequivalent generic version of Novartis AG’s (NVS) Zometa, is used along with anti-cancer drugs to prevent bone fractures in patients with multiple myeloma and prostate cancer and for treating osteoporosis.
This has hiked the values of the firm’s share by nearly 1.06%.
Source-Medindia